Storia in 1 fonti

Exclusive: Akeso pushes back on ASCO questioning of lung cancer drug

Akeso CEO Michelle Xia tells Endpoints the scrutiny of Chinese vs. Western patient data for ivonescimab is overblown, with the FDA deciding on US approval by Nov. 14.

Raccontata da

endpoints.news

Timeline cronologica

venerdì 26 giugno 2026·endpoints.news
Exclusive: Akeso pushes back on ASCO questioning of lung cancer drug
Akeso CEO Michelle Xia tells Endpoints the scrutiny of Chinese vs. Western patient data for ivonescimab is overblown, with the FDA deciding on US approval by Nov. 14.